The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
Now we will, there's a very nuanced case we make, Andrew, which is we'll look at patients with highly suppressed desmosterol levels. We will back off. We do want to maintain desmosterol above a certain level, because of some evidence that is still, I think, very preliminary, but enough for us that we say, why take the chance?
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
if des must roll is below a certain population percentile cut point I've inhibited cholesterol synthesis probably I probably get no bang for the buck on further LDL or a particle lowering April be lowering by having you continue to take that